166 related articles for article (PubMed ID: 8899552)
1. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
Zhang J; Clark JR; Herman EH; Ferrans VJ
J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
Zhang J; Herman EH; Ferrans VJ
Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
[TBL] [Abstract][Full Text] [Related]
3. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
5. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
8. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
Herman EH; Ferrans VJ
Cancer Res; 1981 Sep; 41(9 Pt 1):3436-40. PubMed ID: 6790165
[TBL] [Abstract][Full Text] [Related]
9. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Herman EH; el-Hage A; Ferrans VJ
Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
[TBL] [Abstract][Full Text] [Related]
11. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex.
Herman EH; Zhang J; Hasinoff BB; Clark JR; Ferrans VJ
J Mol Cell Cardiol; 1997 Sep; 29(9):2415-30. PubMed ID: 9299365
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman EH; Zhang J; Ferrans VJ
Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
[TBL] [Abstract][Full Text] [Related]
15. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Baba H; Stephens LC; Strebel FR; Siddik ZH; Newman RA; Ohno S; Bull JM
Cancer Res; 1991 Jul; 51(13):3568-77. PubMed ID: 1905199
[TBL] [Abstract][Full Text] [Related]
18. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.
Dardir M; Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1989; 23(5):269-75. PubMed ID: 2495862
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
